Synthesis, Characterization, In Vitro Cytotoxicity, and Apoptosis-Inducing Properties of Ruthenium(II) Complexes

Li Xu1*, Nan-Jing Zhong2, Yang-Yin Xie3, Hong-Liang Huang4, Guang-Bin Jiang3, Yun-Jun Liu3*

1 School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan, P. R. China, 2 School of Food Science, Guangdong Pharmaceutical University, Zhongshan, P. R. China, 3 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, P. R. China, 4 School of Life Science and Biopharmaceutical, Guangdong Pharmaceutical University, Guangzhou, P. R. China

Abstract

Two new Ru(II) complexes, [Ru(bpy)2(FAMP)](ClO4)2 1 and 2, are synthesized and characterized by elemental analysis, electrospray mass spectrometry, and 1H nuclear magnetic resonance. The in vitro cytotoxicities and apoptosis-inducing properties of these complexes are extensively studied. Complexes 1 and 2 exhibit potent antiproliferative activities against a panel of human cancer cell lines. The cell cycle analysis shows that complexes 1 and 2 exhibit effective cell growth inhibition by triggering G0/G1 phase arrest and inducing apoptosis by mitochondrial dysfunction. The in vitro DNA binding properties of the two complexes are investigated by different spectrophotometric methods and viscosity measurements.

Introduction

Since cisplatin and its platinum complexes were first used as anticancer agents successfully, more active transition metal complexes with better anticancer activity have been studied. Transition metal complexes have potential advantages, such as variable coordination numbers and geometries, accessible redox states, rich physicochemical properties, and extensive structural diversity, over common organic-based drugs. Therefore, the metal-based cancer drug is a focus of research in bioinorganic chemistry [1–6]. Cisplatin is widely used as an anticancer drug to treat many cancers, but severe side effects and acquired resistance caused by prolonged treatment have resulted in the search for alternatives to circumvent drug resistance [7]. With this goal, complexes based on several transition and non-transition metals have been investigated, among which Ru(II) has attracted much attention because of its variable oxidation states, selectivity for cancer cells, low toxicity, and ability to mimic iron when binding to biomolecules [8]. A number of ruthenium complexes display unique antitumor properties, and the treatment is not accompanied by major drug-related side effects [9–11], such as NAMI-A and KP1019, have been used in clinical trials [12–13].

A large number of anthracene analogs have been reported as antiproliferative agents, [Ru(bpy)2(FAMP)](ClO4)2 1 and [Ru(-phen)2(FAMP)](ClO4)2 2, which were obtained by the combination of Ru(II) polypyridyl moieties with anthracene derivative. The antitumor activity, cell cycle arrest and apoptosis, DNA binding, and photocleavage properties of the two complexes were studied.

Experimental Section

Reagents and Materials

All reagents and solvents were purchased commercially and used without further purification unless specially noted. Ultrapure MilliQ water was used in all experiments. Calf thymus DNA (CT DNA) was obtained from the Sino-American Biotechnology Company, pBR 322 DNA was obtained from Shanghai Sangon Biological Engineering&Services Co., Ltd. Dimethyl sulfoxide (DMSO), RPMI 1640 (RPMI = Roswell Park Memorial Institute), 9, 10-bis(chloromethyl)anthracene and 2-nitro-propane were purchased from Sigma. RuCl3 *xH2O was purchased from the Guangzhou Chemical Reagent Factory. Agarose and ethidium bromide were obtained from the Sino-American Biotechnology Company. pBR 322 DNA was obtained from Shanghai Sangon Biological Engineering&Services Co., Ltd. Dimethyl sulfoxide (DMSO), RPMI 1640 (RPMI = Roswell Park Memorial Institute), 9, 10-bis(chloromethyl)anthracene and 2-nitro-propane were purchased from Sigma. RuCl3 *xH2O was purchased from the Kunming Institution of Precious Metals. 1, 10-phenanthroline was obtained from the Guangzhou Chemical Reagent Factory, Cell lines of BEL-7402 (human hepatocellular carcinoma cell line), A549 (human lung adenocarcinoma epithelial cell line), MG-63 (human osteosarcoma cell line), and SKBR-3 (human breast cancer cell line) were purchased from the American Type Culture Collection. Agarose and ethidium bromide were obtained from Aldrich. Doubly distilled water was used to prepare buffers (5 mM Tris(hydroxymethylaminomethane)-HCl, 50 mM NaCl,
pH = 7.2). A solution of calf thymus DNA in the buffer gave a ratio of UV absorbance at 260 and 280 nm of ca. 1.8~1.91, indicating that the DNA was sufficiently free of protein [17]. The DNA concentration per nucleotide was determined by absorption spectrophotometry using the molar absorption coefficient (6600 M$^{-1}$ cm$^{-1}$) at 260 nm [18].

**Physical Measurements**

Microanalyses (C, H, and N) were carried out with a Perkin-Elmer 240Q elemental analyzer. Fast atom bombardment (FAB) mass spectra were recorded on a VG ZAB-HS spectrometer in a 3-nitrobenzyl alcohol matrix. Electrospray ionization mass spectra (ES-MS) were recorded on a LCQ system (Finnigan MAT, USA) using methanol as mobile phase. The spray voltage, tube lens offset, capillary voltage and capillary temperature were set at 4,500 V, 23.00 V and 200°C, respectively, and the quoted m/z values are for the major peaks in the isotope distribution. $^1$H NMR spectra were recorded on a Varian-500 spectrometer with DMSO$_d_6$ as solvent and tetramethylsilane (TMS) as an internal standard at 500 MHz at room temperature. UV/Vis spectra were recorded on a Perkin-Elmer Lambda 55 spectrophotometer and emission spectra were recorded on a Perkin-Elmer LS 55 spectrofluorophotometer at room temperature.

**Synthesis of the Ligand and Complexes**

**Synthesis of 2-[(4-formylanthryl)imidazo-[4,5-f]-[1,10]phenanthroline (FAMP).** A mixture of 9,10-Anthracenedicarboxaldehyde (0.35 g, 1.5 mmol) [19], 1,10-phenanthroline-5,6-dione (0.32 g, 1.5 mmol) [20], ammonium chloride (2.31 g, 30 mmol), and glacial acetic acid (30 cm$^3$) was refluxed with stirring for 2 h. The cooled solution was then diluted with water and neutralized with concentrated aqueous ammonia. The precipitate was collected and purified by column chromatography on silica gel (60–100 mesh) with ethanol as eluent to give the precipitate was collected and purified by column chromatography and neutralized with concentrated aqueous ammonia. The solvent was removed under reduced pressure and a yellow powder was obtained. Yield: 0.51 g, 80%. Anal. Calc. for C$_{28}$H$_{16}$N$_4$O: C, 79.23; H, 3.80; N, 13.20. Found: C, 79.14; H, 3.78; N, 14.16 (s, 1H), 13.08 (s, 1H), 9.08 (d, 2H, $J$=8.5 Hz), 8.94 (d, 2H, $J$=9.0 Hz), 8.87 (d, 2H, $J$=8.0 Hz), 8.83 (d, 4H, $J$=9.0 Hz), 8.76 (d, 2H, $J$=7.5 Hz), 8.51 (d, 2H, $J$=7.0 Hz), 8.21 (t, 2H, $J$=6.0 Hz), 8.13 (d, 2H, $J$=6.5 Hz), 8.08 (t, 2H, $J$=6.0 Hz), 7.97 (d, 2H, $J$=9.0 Hz), 7.94 (d, 4H, $J$=5.5 Hz), 7.57–7.61 (m, 2H), 7.35 (t, 2H, $J$=7.0 Hz).

**Synthesis of [Ru(phen)_2(FAMP)](ClO$_4$)$_2$ (2).** This complex was synthesized by an identical method as described for complex 1, with cis-[Ru(phen)_2Cl$_2$](2H$_2$O) [21] in place of cis-[Ru(bpy)$_2$Cl$_2$](2H$_2$O) as a green precipitate. Yield: 0.36 g, 70%. C$_{48}$H$_{32}$N$_8$Cl$_2$O$_9$Ru: C, 55.61; H, 3.11; N, 10.68%. ES-MS $^{m/z}$: 837.2 ([M–2ClO$_4$–H]$^+$, 443.1 ([M–2ClO$_4$]$^{2+}$). $^1$H NMR (500 MHz, DMSO-d$_6$) $^{m/z}$: $^{8}$H 14.38 (s, 1H), 13.52 (s, 1H), 9.87 (d, 2H, $J$=0.5 Hz), 8.07 (d, 2H, $J$=0.5 Hz), 8.76 (d, 2H, $J$=7.5 Hz), 8.67 (d, 2H, $J$=0.5 Hz), 8.62 (d, 2H, $J$=8.0 Hz), 8.54 (d, 2H, $J$=7.0 Hz), 8.31 (s, 4H), 0.21 (d, 2H, $J$=5.5 Hz), 8.15 (d, 2H, $J$=6.5 Hz), 8.06 (d, 2H, $J$=5.5 Hz), 7.94 (d, 2H, $J$=5.5 Hz), 7.94 (m, 2H), 7.75 (m, 4H).

**Cytotoxicity Assay in vitro**

MTT (3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide) assay procedures were used [22]. Cells were placed in 96-well microassay culture plates (8×10$^4$ cells per well) and grown overnight at 37°C in a 5% CO$_2$ incubator. Complexes were tested then added to the wells to achieve final concentrations ranging from 10$^{-6}$ to 10$^{-4}$ M. Control wells were prepared by addition of culture medium (100 µL). The plates were incubated at 37°C in a 5% CO$_2$ incubator for 48 h. Upon completion of the incubation, stock MTT dye solution (20 µL, 5 mg·mL$^{-1}$) was added to each well. After 4 h, buffer (100 µL) containing N,N-dimethylformamide (50%) and sodium dodecyl sulfate (20%) was added to solubilize the MTT formazan. The optical density of each well was then measured with a microplate spectrophotometer at a wavelength of 490 nm. The IC$_{50}$ values were determined by plotting the percentage viability vs. concentration on a logarithmic graph and reading off the concentration at which 50% of cells remain viable relative to the control. Each experiment was repeated at least three times to obtain the mean values. Four different tumor cell lines were the subjects of this study: BEL-7402, A549, MG-63 and SKBR-3.

**Apoptosis Assay by Hoechst 33258 Staining Method**

BEL-7402 cells were seeded onto chamber slides in six-well plates at a density of 2×10$^4$ cells per well and incubated for 24 h. The cells were cultured in RPMI 1640 supplemented with 10% of fetal bovine serum (FBS) and incubated at 37°C and 5% CO$_2$. The medium was removed and replaced with medium (final DMSO concentration, 1% v/v) containing the complex (12.5 µM)
for 24 h. The medium was removed and the cells were washed with ice-cold PBS, and fixed with formalin (4%, w/v). Cell nuclei were counterstained with Hoechst 33258 (10 μg·mL⁻¹ in PBS) for 10 min. Then the cells were observed and imaged by a fluorescence microscope (Nikon, Yokohama, Japan) with excitation at 350 nm and emission at 460 nm.

Cell Cycle Arrest by Cytometric Analysis

BEL-7402 cells were seeded into six-well plates at a density of 2×10⁵ cells per well and incubated for 24 h. The cells were cultured in RPMI 1640 supplemented with fetal bovine serum (FBS, 10%) and incubated at 37°C and 5% CO₂. The medium was removed and replaced with medium (final DMSO concen-

Figure 1. Hoechst 33258 staining of BEL-7402 cells for 24 h. a) control, b and c treated with 12.5 μM complexes 1 and 2, respectively.
doi:10.1371/journal.pone.0096082.g001

Figure 2. The percentage of Living (L), Necrotic (N) and Apoptotic (A) ruthenium complex-treated BEL-7402 cells as analyzed by FACS calibur flow cytometry. Control (a), 24 h exposed to 6.25 μM (b), 12.5 μM (c) and 25 μM (d) of complex 1.
doi:10.1371/journal.pone.0096082.g002
tration, 1% v/v) containing complexes 1 and 2 (6.25 μM). After incubation for 24 h, the cell layer was trypsinized and washed with cold phosphate buffered saline (PBS) and fixed with 70% ethanol. The fixed cells are rinsed with PBS and then stained with the DNA fluorochrome PI in a solution containing Triton X-100 as well as RNase, keep 15 min at 37°C. Then the samples were analyzed with a FACSCalibur flow cytometer (Becton Dickinson & Co., Franklin Lakes, NJ). The number of cells analyzed for each sample was 10000 [23].

Mitochondrial Membrane Potential Assay

Cells were treated for 24 h with complexes in 12-well plates and were then washed three times with cold PBS. The cells were then detached with trypsin-EDTA solution. Collected cells were incubated for 20 min with 1 μg·mL⁻¹ of JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide) in culture medium at 37°C in the dark. Cells were immediately centrifuged to remove the supernatant. Cell pellets were suspended in PBS and then photographed under a microscope.

DNA Binding and Photoactivated Cleavage

The DNA-binding and photoactivated cleavage experiments were performed at room temperature. Buffer A [5 mM tris(hydroxymethyl)aminomethane (Tris) hydrochloride, 50 mM NaCl, pH 7.0] was used for absorption titration, luminescence titration and viscosity measurements. Buffer B (50 mM Tris-HCl, 18 mM NaCl, pH 7.2) was used for DNA photocleavage experiments.

The absorption titrations of the complex in buffer were performed using a fixed concentration (10 μM) for complex to which increments of the DNA stock solution were added. The intrinsic binding constants \( K_b \), based on the absorption titration, were measured by monitoring the changes of absorption in the MLCT band with increasing concentration of DNA using the equation [24].

Thermal denaturation studies were carried out with a Perkin-Elmer Lambda 35 spectrophotometer equipped with a Peltier temperature-controlling programmer (±0.1°C). The melting temp \( (T_m) \) was taken as the mid-point of the hyperchromic transition. The melting curves were obtained by measuring the absorbance at 260 nm for solns of CT-DNA (100 μM) in the absence and presence of the RuII complex (10 μM) as a function of the temp. The temp was scanned from 30 to 95°C at a speed of 1°C min⁻¹. The data were presented as \((A - A_0)/(A_f - A_0)\) vs. temp., where \(A\), \(A_0\), and \(A_f\) are the observed, the initial, and the final absorbance at 260 nm, resp.

Viscosity measurements were carried out using an Ubbelodhe viscometer maintained at a constant temperature at 25.0 (±0.1°C in a thermostatic bath. DNA samples approximately 200 base pairs in average length were prepared by sonicating in order to minimize complexities arising from DNA flexibility [25]. Flow time was measured with a digital stopwatch, and each sample was measured three times, and an average flow time was calculated. Relative viscosities for DNA in the presence and absence of complexes were calculated from the relation \( \eta = (t/t_0)^{1/3} \) versus binding ratio [26].

For the gel electrophoresis experiment, supercoiled pBR322 DNA (0.1 μg) was treated with the Ru(II) complexes in buffer B, and the solution was then irradiated at room temperature with a UV lamp (365 nm, 10 W). The samples were analyzed by electrophoresis for 1.5 h at 80 V on a 0.8% agarose gel in TBE (89 mM Tris-borate acid, 2 mM EDTA, pH 8.3). The gel was stained with ethidium bromide and photographed under UV light.

![Figure 4. Assay of BEL-7402 cells mitochondrial membrane potential with JC-1 as fluorescence probe staining method.](http://www.plosone.org/)

(a) control, after 24 h exposure to 12.5 μM of (b) complex 1 and (c) complex 2.

doi:10.1371/journal.pone.0096082.g004
stained with 1 µg/ml ethidium bromide and photographed on an Alpha Innotech IS–5500 fluorescence chemiluminescence and visible imaging system.

Results and Discussion

Synthesis and Characterization
An outline of the synthesis of complexes 1 and 2 is presented in Fig. S1. The ligand FAMP was obtained by condensation of 1,10-phenanthroline-5,6-dione with 9,10-anthracenedicarboxaldehyde in refluxing glacial acetic acid containing ammonium acetate at a molar ratio of 1:1. The complexes 1 and 2 were synthesized and high yield was obtained by the direct reaction of FAMP with appropriate precursor complexes in ethanol. The desired Ru(II) complexes were isolated as perchlorates and purified by column chromatography. In the ES–MS spectra of the Ru(II) complexes, the signals of [M-2ClO4-H]+ and [M-2ClO4]2+ were observed. The ES–MS results are provided in the experimental section. The measured molecular weights were consistent with expected values.

Cytotoxicity Assays in vitro
The MTT assay procedures were used to evaluate the in vitro cytotoxicity of complexes 1 and 2 on BEL-7402, A549, MG-63, and SKBR-3 cell lines to determine their potential as anticancer agents. Cisplatin, the ligand FAMP and similar compound [Ru(phen)2(Hecip)](ClO4)2 were included for comparison, and were tested under identical conditions. The above cell lines were treated with different concentrations of complexes 1 and 2 for 48 h. The IC50 values for complexes 1 and 2 against these cell lines are summarized in Table 1. Based on the IC50 values, the newly synthesized complexes 1 and 2 were more active against SKBR-3 cells than against other cancer cells. The ligand FAMP showed less toxicity than complexes 1 and 2. The IC50 values of complexes 1 and 2 toward BEL-7402 cells were lower than that of cisplatin, which indicates that complexes 1 and 2 show higher cytotoxic effect on BEL-7402 cells than cisplatin under identical conditions. Comparing the IC50 values, we also found that complex 1 was effective against BEL-7402 cells. Additionally, complex 2 shows higher cytotoxic activity than complex 1 against A549, MG-63, and SKBR-3 cell lines. The two complexes displayed different cytotoxic effect against different tumor cell lines. At the same time, the compound [Ru(phen)2(Hecip)](ClO4)2 shows lower IC50 values than complex 2 against BEL-7402, A549 and MG-63 cell lines. Based on the results, we speculate that the antitumor activity of complex may be related to the specific molecular shape of the complex and the chemical structure and nature of the inserted ligand.

Apoptosis Assays with Hoechst 33258 Staining and Flow Cytometry

To determine whether or not complexes 1 and 2 induced chromatin condensation and fragmentation, which are recognized morphological features of apoptosis, BEL-7402 cell line was treated with different concentrations of complexes 1 and 2 for 48 h. The IC50 values for complexes 1 and 2 against these cell lines are summarized in Table 1. Based on the IC50 values, the newly synthesized complexes 1 and 2 were more active against SKBR-3 cells than against other cancer cells. The ligand FAMP showed less toxicity than complexes 1 and 2. The IC50 values of complexes 1 and 2 toward BEL-7402 cells were lower than that of cisplatin, which indicates that complexes 1 and 2 show higher cytotoxic effect on BEL-7402 cells than cisplatin under identical conditions. Comparing the IC50 values, we also found that complex 1 was effective against BEL-7402 cells. Additionally, complex 2 shows higher cytotoxic activity than complex 1 against A549, MG-63, and SKBR-3 cell lines. The two complexes displayed different cytotoxic effect against different tumor cell lines. At the same time, the compound [Ru(phen)2(Hecip)](ClO4)2 shows lower IC50 values than complex 2 against BEL-7402, A549 and MG-63 cell lines. Based on the results, we speculate that the antitumor activity of complex may be related to the specific molecular shape of the complex and the chemical structure and nature of the inserted ligand.
treated with complexes 1 and 2 at 12.5 μM for 24 h. As shown in Fig. 1, green apoptotic cells showing apoptosis characteristics such as nuclear shrinkage, chromatin condensation were observed. Complexes 1 and 2 can induce apoptosis in BEL-7402 cells.

To determine the percentage of the necrotic or late apoptotic cells and early apoptotic BEL-7402 cells, the cells were treated with 6.25, 12.5 and 25 μM of complex 1 for 24 h. After treatment, cell apoptosis analyses were performed using flow cytometry. As shown in Fig. 2, at a concentration as low as 6.25 μM, 3.02% of the BEL-7402 cells were in the early apoptotic phase, whereas 22.77% of the cells were in the late apoptotic phase. However, at 12.5 and 25 μM, a total of 25.34% and 34.65% of the cells were undergoing apoptosis (early apoptotic+late apoptotic), respectively, whereas the untreated cells remained 100% viable. The cell death induced by complex 1 follows a pathway from the viable cells to the early apoptotic cells and then to the necrotic or late apoptotic cells. This pathway suggests that induced cell death occurs mainly through apoptosis. Furthermore, the effect increases significantly in a dose-dependent manner.

**Cell Cycle Arrest Studies**

Flow cytometry was used to determine the effects of complexes 1 and 2 on the cell cycle progression of BEL-7402 cells. The cell cycle distribution after treating BEL-7402 cells with complexes 1 or 2 at 6.25 and 12.5 μM for 24 h is shown in Fig. 3. The percentage of cells at the G0/G1 phase showed an evident increase of 14.37% and 15.06% for complex 1 and 11.24% and 12.90% for complex 2 at 6.25 and 12.5 μM, respectively, which was accompanied by a corresponding reduction in the percentage of cells in the S and G2/M phases. Obviously, complex 1 caused more pronounced changes in the cell cycle than complex 2 in the G0/G1 phase under identical conditions. The antiproliferative mechanism induced by complexes 1 or 2 on BEL-7402 cells was G0/G1 phase arrest, and the changes in percentages at G0/G1 and S phases were concentration dependent.

**Mitochondrial Membrane Potential Detection**

JC-1 was used as a fluorescence probe in detecting the change of mitochondrial membrane potential induced by complexes 1 and 2. At high mitochondrial potential, JC-1 forms aggregates, which have a red fluorescence emission peak. At low mitochondrial membrane potential, JC-1 forms monomers, which emit a green fluorescence peak. As shown in Fig. 4, JC-1 exhibits a red fluorescence (JC-1 aggregates) with high mitochondrial membrane potential in the control. After exposure of BEL-7402 cells to 12.5 μM concentration of complexes 1 and 2 for 24 h, JC-1 showed green fluorescence (JC-1 monomers) corresponding to low mitochondrial membrane potential. The change from red to green fluorescence suggests the decrease of mitochondrial membrane potential in the presence of complexes 1 and 2, which indicates that complexes 1 and 2 induced apoptosis in BEL-7402 cells through the mitochondrial signal transduction pathway.

**Electronic Absorption Spectra Studies**

The absorption spectra of complexes 1 and 2 in the presence of increasing amounts of calf thymus DNA (CT DNA) are shown in Fig. 5. The lowest energy bands at 447 nm for complex 1 and 477 nm for complex 2 were assigned to the metal-to-ligand charge transfer transitions. The bands below 300 nm were attributed to π–π* transitions. The bands below 300 nm were attributed to intraligand π–π* transitions. As the concentration of CT DNA increased, the MLCT transition band of complexes 1 and 2 exhibited hypochromism of 14.68% and 17.20%, respectively. The values of K for complexes 1 and 2 were 0.80 ± 0.24 × 10^5 M^-1 (s = 1.88) and 1.70 ± 0.25 × 10^5 M^-1 (s = 2.59), respectively. These values were smaller than those of [Ru(bpy)_2(dppz)]^{2+} (4.9 × 10^5 M^-1) [28] and [Ru(phen)_2(dppz)]^{2+} (5.1 × 10^6 M^-1) [28], but were comparable with those of Δ-[Ru(phen)_2(dpz)]^{2+} (3.2 × 10^5 M^-1) and Δ-[Ru(phen)_2(dpz)]^{2+} (1.7 × 10^3 M^-1) [29], and were much larger than those of other typical DNA intercalative Ru(II) complexes (1.1 × 10^3 M^-1 to 4.8 × 10^3 M^-1). The complexes intercalatively bind to DNA, which involves a strong stacking interaction between the aromatic
chromophore and the base pairs of the DNA. Additionally, the larger DNA binding constant of complex 2 reflects its higher binding affinity and deeper intercalation than complex 1.

Luminescence Studies

The absorption titrations and the luminescence studies confirm the satisfactory DNA binding abilities of complexes 1 and 2. In the absence of DNA, complexes 1 and 2 can emit luminescence in Tris buffer at ambient temperature, with maximum luminescence appearing at 596 and 605 nm, respectively. With CT DNA addition, the emission intensities of complexes 1 and 2 increased to approximately 1.3 and 1.5 times the original intensities, respectively (Fig. 6), which implies that both complexes can interact with DNA and were protected by DNA efficiently. The increase in luminescence intensity is due to two factors: first, the hydrophobic environment inside the DNA helix reduces the accessibility of solvent water molecules to the complex; and second, the complex mobility is restricted at the binding site, leading to a decrease of the vibrational modes of relaxation. On the other hand, We found that the tendency of luminescent changes between complexes 1 and 2 is different. For complex 1, the peak width became narrow with increasing concentration of DNA. However, The complex 2 displays a large red shift of the peak. The different luminescence behaviours of the complex-DNA system are mainly relevant to the affinity of the complex to DNA and the binding environment around the two molecules [30].

DNA Thermal Denaturation Studies

DNA melting experiments can establish the extent of intercalation because the intercalation of the complex into DNA base pairs causes stabilization of base stacking, and therefore, raises the melting temperature of double-stranded DNA [31]. With increasing solution temperature, the double-stranded DNA gradually dissociates to single strands and generates a hyperchromic effect on the absorption spectra of the DNA bases ($\lambda_{\text{max}} = 260 \text{ nm}$). To identify this transition process, the melting temperature $T_m$ defined as the temperature when half of the total base pairs is dissociates to single strands and generates a hyperchromic effect on CT DNA in the absence and presence of the complex are presented in Fig. 7. The thermal denaturation experiment performed for DNA in the absence of the Ru(II) complexes revealed a $T_m$ of 60.5$\pm$0.2°C under our experimental conditions. The observed melting temperature in the presence of complexes 1 and 2 was 69.0$\pm$0.1°C and 74.2$\pm$0.2°C, respectively, at a concentration ratio of $r = 0.10$ ($r = [\text{Ru}] / [\text{DNA}]$). The $\Delta T_m$ values (8.5°C and 13.7°C) of complex 1/2-DNA adducts are comparable to that observed for classical intercalators ethidium bromide (13°C, $r = 0.10$), $\Delta [\text{Ru(phen)$_2$(dppz)Cl}]^{2+}$ (16°C, $r = 1$), and $\Delta [\text{Ru(phen)$_2$(dppz)Cl}]^{2+}$ (5°C, $r = 1$) [29]. The results also suggest the intercalative binding mode of complexes 1 and 2 to DNA.

Viscosity Measurements

Relative viscosity measurements have been effective as a method for the assignment of the mode of binding compounds to DNA. In classical intercalation, the DNA helix lengthened as base pairs are separated to accommodate the binding ligand that increases DNA viscosity, whereas a partial, non-classical ligand intercalation causes a bend in the DNA helix reducing its effective length, and consequently, its viscosity. The viscosity studies provide a stronger argument for intercalation [33]. The effects of the complexes 1 and 2 on the viscosity of CT-DNA are shown in Fig. 8. As illustrated in Fig. 8, increasing the amount of the two complexes leads to a steady increase in the relative viscosity of CT DNA, which proves that the two complexes bind to DNA by classical intercalation. The increased degree of viscosity, which depends on the affinity of the complexes to the DNA, follows the order of complex 2$\geq$ complex 1. The results are consistent with our conclusions.

DNA Photocleavage

When circular plasmid DNA is subject to electrophoresis, relatively fast migration is observed for the intact supercoiled form (Form I). If scission occurs on one strand (nicked), the supercoiled form will relax to generate a slower-moving, open circular form (Form II) [34]. The cleavage of plasmid DNA in the absence or presence of complexes 1 and 2 was monitored by agarose gel electrophoresis. The DNA cleaving efficiencies of these complexes are shown in Fig. 9. No obvious DNA cleavage was observed in the controls that do not contain the complexes, or when the plasmid was incubated with the Ru(II) complex in the dark. In the presence of different concentrations of the complexes, the Form I amount of pBR322 DNA decreased, whereas that of Form II increased. These results indicate that these complexes can effectively cleave pBR322 DNA upon irradiation.

Conclusions

Two new Ru(II) complexes were synthesized and characterized. The cytotoxicity assay shows that complexes 1 and 2 can suppress tumor cell proliferation. Notably, the antiproliferative activities of complexes 1 and 2 are much higher than that of the ligand FAMP, suggesting that the significantly higher anticancer activity is due to the complexation with Ru(II) polypyridyl moieties. The apoptotic study indicates that complexes 1 and 2 can effectively induce apoptosis of BEL-7402 cells and inhibit the proliferation in the G0/G1 phase on BEL-7402 cells. Additionally, complexes 1 and 2 induce a decrease of the mitochondrial membrane potential. The complexes induce apoptosis of BEL-7402 cells through the mitochondrial signal transduction pathway. The DNA-binding behavior show that the two complexes interact with CT DNA through intercalative mode. Upon irradiation, these complexes can effectively cleave pBR322 DNA. These results will help in designing highly cytotoxic Ru(II) complexes and DNA-binding reagents.

Supporting Information

Figure S1 Synthetic route of complexes 1 and 2. (TIF)

Author Contributions

Conceived and designed the experiments: LX HLH YJL. Wrote the paper: LX. Contributed reagents/materials/analysis tools: YJL. Performed the experiments: LX NJZ YYX GBJ. Analyzed the data: LX HLH YJL.

References

1. Jung Y, Lippard SJ (2007) Direct cellular responses to platinum-induced DNA damage. Chem Rev 107: 1307–1407.

2. Hartinger CG, Nazarov AA, Ashraf SM, Dyson PJ, Keppler BK (2008) Carbohydrate-metal complexes and their potential as anticancer agents. Curr Med Chem 15: 2574–2591.
3. Liu YN, Zhang XN, Zhang R, Chen TF, Wong YS, et al. (2011) Ruthenium-porphyrin complexes induce apoptosis by inhibiting the generation of intracellular reactive oxygen species in the human hepatoma cell line (HepG2). Eur J Inorg Chem 1974–1980.

4. Grau-Campistany A, Massagué A, Carrion-Salip D, Barragan F, Artigas G, et al. (2013) Conjugation of a Ru(II) arene complex to neomycin or to guanidino-1,2,3-oxadiazoles leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells. Mol Pharmaceutics 10: 1964–1976.

5. Palaninurug D, Shinde SV, Somasundaram K, Samuelson AG (2013) In vitro and in vivo anticancer activity of copper bis(hydroxamicarbazone) complexes. J Med Chem 56: 722–734.

6. Gupta RK, Pandey R, Sharma G, Prasad R, Koch B, et al. (2013) DNA binding and anti-cancer activity of redox-active heteroleptic piano-stool Ru(II), Rh(III), and Ir(III) complexes containing 4-(2-methoxy)pyridylphenylpyrroloethene. Inorg Chem 52: 3607–3690.

7. Rabik CA, Dobos ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9–23.

8. Smith GS, Therrien B (2011) Targeted and multifunctional arene ruthenium chemotherapeutics. Dalton Trans 40: 16795–16800.

9. Misoguchi G, Herbst RS, Manegold C, Scaglioni G, Rosell R, et al. (2004) Gefitinib in combination with gemcitabine and erlotinib in advanced non–small-cell lung cancer: a phase III trial. J Clin Oncol 22: 774–784.

10. Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic anticancer compounds. J Med Chem 54: 3–25.

11. Clarke M (2003) Ruthenium metallopharmaceuticals. J Coord Chem Rev 236: 209–233.

12. Bratsos I, Jedner S, Gianferrara T, Alessio E (2007) Ruthenium anticancer drugs. J Med Chem 50: 3–25.

13. Rabik CA, Dobos ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9–23.

14. Zhang HY, Wang HP, Cui HL, Li ZG, Xie ZP, et al. (2011) A new anthracene bishydrazone, 9,10-anthracenedicarboxaldehyde bis[4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride against experimental tumors in mice. Cancer Res 71: 440–444.

15. Citarella RV, Wallace RE, Murdock KC (1982) Activity of a novel anthracenyl cytidine triphosphate in hybrid G-quadruplex DNA by a ruthenium polypyridyl complex. Chem Commun 48: 10781–10783.

16. Neves JA, Barros CA, Saraiva TF, Ribeiro SV, Silva AM, et al. (2013) Conjugation of a Ru(II) arene complex to neomycin or to guanidino-1,2,3-oxadiazoles leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells. Mol Pharmaceutics 10: 1964–1976.

17. Marmur J (1961) A procedure for the isolation of desoxyribonucleic acid from micro-organisms. J Mol Biol 3: 208–218.

18. Reichman ME, Rice SA, Thomas CA, Doty P (1954) A further examination of the molecular weight and size of desoxypentose nucleic acid. J Am Chem Soc 76: 3047–3053.

19. Landerman BH (1966) Alddehyde synthesis. a study of the preparation of 9,10-anthracenedicarboxaldehyde and other aromatic dialdehydes. J Org Chem 31: 2618–2620.

20. Paw W, Eisenberg R (1997) Synthesis, characterization, and spectroscopy of dipridocatexate complexes of platinum. Inorg Chem 36: 2287–2293.

21. Sullivan BP, Salmon DJ, Meyer TJ (1976) Mixed phosphine 2,2’-bipyridine complexes of ruthenium. Inorg Chem 17: 3334–3341.

22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 35–63.

23. Lo KK, Lee TK, Lau JS, Poon WS, Cheng SH (2008) Luminol-enhanced biological probes derived from ruthenium(II) estradiol polypyridine complexes. Inorg Chem 47: 200–208.

24. Wolfe A, Shiner Jr GH, Mechan T (1987) Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. Biochemistry 26: 6392–6396.

25. Chaires JB, Dattagupta N, Crotthers DM (1982) Studies on interaction of anthracene antibiotics and desoxyribonucleic acid: equilibirium binding studies on the interaction of daunomycin with desoxyribonucleic acid. Biochemistry 21: 3933–3940.

26. Satyanarayana S, Babu KL, Chaires JB (1993) Tris(phenanthroline)ruthenium(II) enammoner interactions with DNA: Mode and specificity of binding. Biochemistry 32: 2573–2584.

27. Cohen G, Eisenberg H (1969) Viscosity and sedimentation study of sonicated DNA-proflavine complexes. Biopolymers 8: 45–55.

28. Friedman AE, Chamberon JC, Sauvage JP, Tarr T, Barton JK (1990) A molecular light switch for DNA: Ru(bpy)2(dppz)2[Fe]2+. J Am Chem Soc 112: 4960–4962.

29. Han MJ, Duan ZM, Hao Q, Zhong SZ, Wang KZ (2007) Molecular light switches for calf thymus DNA based on three Ru(II) bipyridyl complexes with variations of heteroatoms. J Phys Chem C 111: 16577–16583.

30. Liao GL, Chen X, Ji LN, Zhao H (2012) Visual specific luminescent probing of hybrid G-quadruplex DNA by a ruthenium polypyrpyridyl complex. Chem Commun 48: 10781–10783.

31. Tieleman-Boelkovic G, Katsaros N (1989) The interaction of [Ru(NH3)6][Cl2]2+ and [Ru(NH3)6]4+ ions with DNA. J Inorg Biochem 37: 271–292.

32. Neyhart GA, Grover N, Smith SR, Kalsbeck WA, Fairley TA, et al. (1993) Conjugation to neomycin. Cancer Res 42: 440–444.

33. Siegel D, Haddad J (1986) Antitumor Behaviors of Ruthenium(II) Complexes